Marine-Derived Streptomyces sennicomposti GMY01 with Anti-Plasmodial and Anticancer Activities: Genome Analysis, In Vitro Bioassay, Metabolite Profiling, and Molecular Docking

To discover novel antimalarial and anticancer compounds, we carried out a genome analysis, bioassay, metabolite profiling, molecular docking of marine sediment actinobacteria strain GMY01. The whole-genome sequence analysis revealed that Streptomyces sp. GMY01 (7.9 Mbp) is most similar to sennicomposti RCPT1-4T with an average nucleotide identity (ANI) ANI based on BLAST+ (ANIb) values 98.09 97.33% (>95%). An in vitro bioassay the bioactive Plasmodium falciparum FCR3, cervical carcinoma HeLa cell lung HTB cells exhibited moderate activity (IC50 value 46.06; 27.31 33.75 µg/mL) low toxicity Vero as normal 823.3 µg/mL). Metabolite profiling by LC-MS/MS active fraction contained carbohydrate-based C17H29NO14 (471.15880 Da) major compound (97.50%) mannotriose (C18H32O16; 504.16903 Da, 1.96%) minor compound. Molecular showed has binding affinity glutathione reductase (GR) glutathione-S-transferase (GST) P. autophagy proteins (mTORC1 mTORC2) cancer cells. potential bacterium producing compounds anti-plasmodial activities